NVE Corporation (NVK.F)
| Previous close | 70.00 |
| Open | 69.50 |
| Bid | 70.50 x 10000 |
| Ask | 72.00 x 10000 |
| Day's range | 69.50 - 69.50 |
| 52-week range | 60.00 - 91.00 |
| Volume | |
| Avg. volume | 6 |
| Market cap | 338.745M |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | 21.38 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.71 (5.29%) |
| Ex-dividend date | 10 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
Dr. Kelly Wei Joins NVE Corporation’s Board of Directors
EDEN PRAIRIE, Minn., May 13, 2024 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced today that its Board of Directors elected Kelly Wei, Ph.D. to join the Board, effective today, filling the unexpired term of Richard W. Kramp, who passed away recently. Dr. Wei will also serve on the Board’s Compensation Committee and Nominating and Corporate Governance Committee. Mr. Kramp’s unexpired term ends at NVE’s 2024 annual shareholders’ meeting. The Board expects to nominate Dr. Wei for a ful
- GlobeNewswire
NVE Corporation Announces Death of Board Member Richard W. Kramp
EDEN PRAIRIE, Minn., May 06, 2024 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced with sadness that Richard W. Kramp, a member of the Company’s Board of Directors, passed away after an illness. Mr. Kramp was first elected to NVE’s Board in 2014 after a long and distinguished career in the medical device industry. Most recently, he was CEO of Synovis Life Technologies, Inc., a diversified medical device company, from 2007 to 2012. “Rich has been a valuable member of our Board of Dire
- GlobeNewswire
NVE Corporation Reports Fourth Quarter and Fiscal Year Results and Announces Quarterly Dividend
EDEN PRAIRIE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- NVE Corporation (Nasdaq: NVEC) announced today financial results for the quarter and fiscal year ended March 31, 2024. Total revenue for the fourth quarter of fiscal 2024 decreased 45% to $7.08 million from $12.8 million for the prior-year quarter. The decrease was due to a 43% decrease in product sales and an 88% decrease in contract research and development revenue. Net income for the fourth quarter of fiscal 2024 decreased 54% to $3.81 mil
